查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529763

纳曲酮和Buprenornhine的全球市场规模、份额和趋势分析：按产品、给药途径、应用、分销管道、地区和细分市场进行预测（2024-2030）

Naltrexone And Buprenorphine Market Size, Share & Trends Analysis Report By Product, By Route of Administration (Oral, Injectable) By Application, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 202 Pages | 商品交期: 2-10个工作天内

价格

纳曲酮和Buprenornhine市场成长和趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球纳曲酮和Buprenornhine市场规模将达到84.2亿美元，2024年至2030年复合年增长率为12.41%。推动该市场成长的主要因素是物质使用障碍发生率的上升、政府加强应对危机情况的力度以及对阿片类药物使用障碍治疗的认识不断提高。预计这些因素将在预测期内显着促进该行业的扩张，推动进步并提高成瘾护理解决方案的可及性。

《2023 年世界毒品报告》强调了吸毒障碍的全球趋势，强调鸦片类药物是过量摄取死亡的主要原因，也是导致残疾和过早死亡的重要原因。阿片类药物使用障碍 (OUD) 影响着全世界数百万人，而 COVID-19 大流行加剧了治疗取得方面的差异。主要滥用药物存在地区差异，包括欧洲和亚洲的鸦片类药物、拉丁美洲的可卡因以及东亚和东南亚的甲基安非他命。耻辱和歧视阻碍了治疗工作，只有不到 20% 的需要治疗的人接受了治疗。报告呼吁国际合作应对这些复杂的健康和社会挑战。

此外，各国政府正在加强以多方面的方式应对 OUD 危机。 2024 年 2 月，经 SAMHSA核准，社区心理健康服务整笔拨款和药物使用预防、治疗和康復服务整笔拨款中的 4660 万美元分配给了心理健康和药物使用服务。此外，美国财政部已指定 6,750 万美元资金用于支持威斯康辛州的这些努力。

此外，产业参与者还透过加强分销网络、与医疗保健提供者建立策略联盟以及增加研发投资等策略措施来推动市场成长。例如，2023年7月，Titan Pharmaceuticals, Inc.和Fedson, Inc.签订了一项资产购买协议，根据该协议，Titan将出售ProNeura的部分资产。该交易包括一系列药物成瘾治疗和其他基于 ProNeura 药物传输技术的早期开发倡议。该公司的药物成瘾产品组合包括纳美芬和普布啡植入计画。此外，Camurus AB 于 2023 年 9 月推出了 Brixadi，这是一种每週一次和每月一次的药物，含有 Brixadi，适用于治疗中度至重度 OUD。这些努力旨在扩大治疗的可及性和有效性，并显着推动进展。

纳曲酮和Buprenornhine市场报告亮点

  • 受强大的医疗基础设施、物质使用障碍的高盛行率以及政府积极支持成瘾治疗的推动，北美在 2023 年占据最大的销售份额，达到 39.39%。
  • 按产品划分，Buprenornhine细分市场在 2023 年占据市场主导地位，份额为 70.02%，预计在预测期内将以最快的复合年增长率成长。该行业的成长可归因于主要企业采取的各种策略，包括产品发布、合作伙伴关係、併购、监管核准、证明疗效的临床试验以及其他提高治疗启动率的因素。
  • 从给药途径来看，2023年口服给药占最大份额，达55.87%。然而，在Buprenornhine细分市场中，注射给药占2023年的大部分份额，达65.04%。
  • 以应用程式来看，2023年OUD细分市场占比为69.03%。纳曲酮被广泛认为可有效治疗 OUD，从而在治疗方案中广泛采用。
  • 从通路来看，2023年院内药局占比48.26%，占全球市场主导地位。医院药房的增长是由于它们在註射Buprenornhine等 OUD 药物、确保治疗由医生监督以及促进获得基本药物方面发挥关键作用。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章纳曲酮和Buprenornhine市场变数、趋势和范围

  • 纳曲酮和Buprenornhine市场阵容展望
    • 母市场展望
    • 配套市场前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 纳曲酮和Buprenornhine市场分析工具
    • 波特五力分析
    • PESTLE分析
  • 管道分析
  • 价格分析
  • 选择植入治疗时患者和提供者的考量因素
  • 目标人口分析
  • 纳曲酮和Buprenornhine皮下可吸收植入的整体潜在市场 (TAM) 分析

第四章纳曲酮和Buprenornhine市场分析：依产品（2018-2030）

  • 纳曲酮和Buprenornhine：产品变异性分析
  • 纳曲酮和Buprenornhine市场分析：按产品市场
  • 纳曲酮
    • 市场收益估算与预测（2018-2030）
  • Buprenornhine
    • 市场收益估算与预测（2018-2030）
    • 贝尔布卡
    • 子位置
    • 赛博松
    • 祖布索尔夫
    • 其他的

第五章纳曲酮和Buprenornhine市场分析：依给药途径（2018-2030）

  • 纳曲酮和Buprenornhine：给药途径变异分析
  • 纳曲酮和Buprenornhine市场分析：按给药途径市场
  • 纳曲酮
    • 市场收益估算与预测（2018-2030）
    • 口服给药
    • 注射给药
    • 植入式给药
  • Buprenornhine
    • 市场收益估算与预测（2018-2030）
    • 口服给药
    • 注射给药
    • 植入式给药

第六章 纳曲酮和Buprenornhine市场分析：依应用分类（2018-2030）

  • 纳曲酮和Buprenornhine：使用变化分析
  • 纳曲酮和Buprenornhine市场分析：按应用市场
  • 纳曲酮
    • 市场收益估算与预测（2018-2030）
    • 阿片类药物使用疾患 (OUD)
  • Buprenornhine
    • 市场收益估算与预测（2018-2030）
    • 阿片类药物使用疾患 (OUD)

第 7 章 纳曲酮与Buprenornhine市场分析：依通路（2018-2030）

  • 纳曲酮和Buprenornhine：分销管道变化分析
  • 纳曲酮和Buprenornhine市场分析：按分销通路市场
  • 医院药房
    • 市场收益估算与预测（2018-2030）
  • 零售药房
    • 市场收益估算与预测（2018-2030）
  • 其他的
    • 市场收益估算与预测（2018-2030）

第八章纳曲酮和Buprenornhine市场：按产品、给药途径、应用和分销管道分類的区域估计和趋势分析

  • 纳曲酮和Buprenornhine市场：区域展望
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第9章 竞争格局

  • 市场参与企业分类
  • 主要企业简介
    • Indivior PLC
    • Collegium Pharmaceutical, Inc.（BioDelivery Sciences International, Inc. 的母公司）
    • Alkermes plc
    • Orexo AB
    • Titan Pharmaceuticals, Inc.
    • Omeros Corporation
    • F. Hoffmann-La Roche Ltd.
    • Camurus
    • Sun Pharmaceutical Industries Ltd
    • Braeburn, Inc.
Product Code: GVR-4-68040-342-4

Naltrexone And Buprenorphine Market Growth & Trends:

The global naltrexone and buprenorphine market size is expected to reach USD 8.42 billion by 2030, growing at a CAGR of 12.41% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is experiencing growth primarily due to the rising incidence of substance use disorders, increasing government efforts to address the crisis, and growing awareness of treatments for opioid use disorder. These factors are anticipated to substantially boost industry expansion during the forecast period, fostering advancements and improving accessibility to addiction care solutions.

The World Drug Report 2023 highlights global trends in drug use disorders, emphasizing opioids as the primary cause of death from overdose and significant contributors to years lost due to disability and premature death. Opioid Use Disorder (OUD) affects millions worldwide, with disparities in treatment access exacerbated by the COVID-19 pandemic. Regional variations in primary drugs of abuse include opioids in Europe and Asia, cocaine in Latin America, and methamphetamine in East & Southeast Asia. Stigma and discrimination hinder treatment efforts, with less than 20% of those needing help receiving it. The report calls for international cooperation to address these complex health and societal challenges.

Furthermore, increasing government initiatives to combat the OUD crisis through multifaceted approaches are growing. In February 2024, with the approval of the SAMHSA, USD 46.6 million in supplemental Community Mental Health Services Block Grant and Substance Use Prevention, Treatment, and Recovery Services Block Grant funds have been allocated to mental health and substance use services. In addition, USD 67.5 million from U.S. Department of Treasury funds has been directed to support these efforts in Wisconsin.

Moreover, industry players are driving growth in the market through strategic initiatives, such as enhanced distribution networks, strategic partnerships with healthcare providers, and increased research and development investments. For instance, in July 2023, Titan Pharmaceuticals, Inc. and Fedson, Inc. signed an Asset Purchase Agreement, under which Titan would sell part of ProNeura assets, such as its portfolio of medications for drug addiction and other early development initiatives built on the ProNeura drug delivery technology. The company's addiction portfolio comprised implant programs for Nalmefene and Probuphine. In addition, in September 2023, Camurus AB introduced Brixadi, a weekly and monthly medication containing Brixadi, indicated to treat moderate-to-severe OUD. These efforts aim to expand treatment accessibility and efficacy, propelling advancement significantly.

Naltrexone And Buprenorphine Market Report Highlights:

  • North America accounted for the largest revenue share of 39.39% in 2023, driven by robust healthcare infrastructure, high prevalence of substance use disorder, and proactive government initiatives supporting addiction treatment.
  • Based on product, the buprenorphine segment dominated the market with a share of 70.02% in 2023 and is anticipated to witness the fastest growth at a CAGR over the forecast period. The segment growth can be attributed to the various strategies adopted by key players such as product launches, collaboration, M&A, regulatory approvals, clinical trials proving efficacy, & other factors that enhance treatment initiation rates.
  • Based on route of administration, the oral administration segment held the majority share of 55.87% in 2023. However, in buprenorphine segment, the injectable administration segment held the majority share of 65.04% in 2023.
  • Based on application, the OUD segment dominated the market with a share of 69.03% in 2023. Naltrexone is widely recognized for their efficacy in managing OUD, leading to its extensive adoption in treatment programs.
  • Based on distribution channel, the hospital pharmacies segment dominated the global market with a share of 48.26% in 2023. Growth can be attributed to their key role in administering parenteral OUD treatments, such as buprenorphine, ensuring physician-supervised care, and facilitating access to essential medications.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Route of Administration
    • 1.2.3. Application
    • 1.2.4. Distribution channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product and Route of Administration Segment Snapshot
  • 2.3. Application and Distribution Channel Segment Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Naltrexone and Buprenorphine Market Variables, Trends, and Scope

  • 3.1. Naltrexone and Buprenorphine Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing prevalence of substance use disorders
      • 3.2.1.2. Growing government initiatives to combat the crisis
      • 3.2.1.3. Increasing awareness of opioid use disorder treatment
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Retention and adherence challenges
  • 3.3. Naltrexone and Buprenorphine Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTLE Analysis
  • 3.4. Pipeline Analysis
  • 3.5. Pricing Analysis
  • 3.6. Patient and Provider Considerations in Choosing Implantable Treatments
  • 3.7. Target Population Analysis
  • 3.8. Total Addressable Market (TAM) Analysis for Naltrexone & Buprenorphine Subcutaneous Absorbable Implants

Chapter 4. Naltrexone and Buprenorphine Market Analysis, by Product, 2018 - 2030 (USD Million)

  • 4.1. Naltrexone and Buprenorphine: Product Movement Analysis
  • 4.2. Naltrexone and Buprenorphine Market Analysis, by Product Market (USD Million)
  • 4.3. Naltrexone
    • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Buprenorphine
    • 4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. BELBUCA
      • 4.4.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Sublocade
      • 4.4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Suboxone
      • 4.4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.5. Zubsolv
      • 4.4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Naltrexone and Buprenorphine Market Analysis, by Route of Administration, 2018 - 2030 (USD Million)

  • 5.1. Naltrexone and Buprenorphine: Route of Administration Movement Analysis
  • 5.2. Naltrexone and Buprenorphine Market Analysis, by Route of Administration Market (USD Million)
  • 5.3. Naltrexone
    • 5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. Oral Administration
      • 5.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Injectable Administration
      • 5.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.4. Implantable Administration
      • 5.3.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Buprenorphine
    • 5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Oral Administration
      • 5.4.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Injectable Administration
      • 5.4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. Implantable Administration
      • 5.4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Naltrexone and Buprenorphine Market Analysis, by Application, 2018 - 2030 (USD Million)

  • 6.1. Naltrexone and Buprenorphine: Application Movement Analysis
  • 6.2. Naltrexone and Buprenorphine Market Analysis, by Application Market (USD Million)
  • 6.3. Naltrexone
    • 6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. Opioid use disorder (OUD)
      • 6.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.2.2. Alcohol use disorder (AUD)
      • 6.3.2.3. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Buprenorphine
    • 6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Opioid use disorder (OUD)
      • 6.4.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Naltrexone and Buprenorphine Market Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

  • 7.1. Naltrexone and Buprenorphine: Distribution Channel Movement Analysis
  • 7.2. Naltrexone and Buprenorphine Market Analysis, by Distribution Channel Market (USD Million)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Others
    • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Naltrexone and Buprenorphine Market: Regional Estimates and Trend Analysis by Product, by Route of Administration, by Application, by Distribution Channel

  • 8.1. Naltrexone and Buprenorphine Market: Regional Outlook
  • 8.2. North America
    • 8.2.1. North America Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. U.S. Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.2.2.3. Competitive/Market Scenario
      • 8.2.2.4. Regulatory Framework
      • 8.2.2.5. Reimbursement scenario
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Canada Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.2.3.3. Competitive/Market Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Mexico Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.2.4.3. Competitive/Market Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Reimbursement Scenario
  • 8.3. Europe
    • 8.3.1. Europe Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. UK Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.2.3. Competitive/Market Scenario
      • 8.3.2.4. Regulatory Framework
      • 8.3.2.5. Reimbursement Scenario
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Germany Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.3.3. Competitive/Market Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. France Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.4.3. Competitive/Market Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
    • 8.3.5. Spain
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Spain Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.5.3. Competitive/Market Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
    • 8.3.6. Italy
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Italy Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.6.3. Competitive/Market Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Denmark Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.7.3. Competitive/Market Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Sweden Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.8.3. Competitive/Market Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
    • 8.3.9. 6.3.9 Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Norway Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.9.3. Competitive/Market Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Rest of Europe Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Naltrexone and Buprenorphine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Japan Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.4.2.3. Competitive/Market Scenario
      • 8.4.2.4. Regulatory Framework
      • 8.4.2.5. Reimbursement Scenario
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. China Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.4.3.3. Competitive/Market Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. India Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.4.4.3. Competitive/Market Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
    • 8.4.5. Australia
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Australia Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.4.5.3. Competitive/Market Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
    • 8.4.6. Thailand
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Thailand Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.4.6.3. Competitive/Market Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
    • 8.4.7. South Korea
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. South Korea Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.4.7.3. Competitive/Market Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Rest of Asia Pacific Naltrexone and Buprenorphine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Brazil Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.5.2.3. Competitive/Market Scenario
      • 8.5.2.4. Regulatory Framework
      • 8.5.2.5. Reimbursement Scenario
    • 8.5.3. Argentina
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Argentina Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.5.3.3. Competitive/Market Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Rest of Latin America Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. 6.6 MEA
    • 8.6.1. MEA Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. South Africa Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.6.2.3. Competitive/Market Scenario
      • 8.6.2.4. Regulatory Framework
      • 8.6.2.5. Reimbursement Scenario
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Saudi Arabia Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.6.3.3. Competitive/Market Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. UAE Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.6.4.3. Competitive/Market Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Kuwait Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.6.5.3. Competitive/Market Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
    • 8.6.6. Rest of MEA Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Key Company Profiles
    • 9.2.1. Indivior PLC
      • 9.2.1.1. Company overview
      • 9.2.1.2. Financial performance
      • 9.2.1.3. Product benchmarking
      • 9.2.1.4. Strategic initiatives
    • 9.2.2. Collegium Pharmaceutical, Inc. (Parent company of BioDelivery Sciences International, Inc.)
      • 9.2.2.1. Company overview
      • 9.2.2.2. Financial performance
      • 9.2.2.3. Product benchmarking
      • 9.2.2.4. Strategic initiatives
    • 9.2.3. Alkermes plc
      • 9.2.3.1. Company overview
      • 9.2.3.2. Financial performance
      • 9.2.3.3. Product benchmarking
      • 9.2.3.4. Strategic initiatives
    • 9.2.4. Orexo AB
      • 9.2.4.1. Company overview
      • 9.2.4.2. Financial performance
      • 9.2.4.3. Product benchmarking
      • 9.2.4.4. Strategic initiatives
    • 9.2.5. Titan Pharmaceuticals, Inc.
      • 9.2.5.1. Company overview
      • 9.2.5.2. Financial performance
      • 9.2.5.3. Product benchmarking
      • 9.2.5.4. Strategic initiatives
    • 9.2.6. Omeros Corporation
      • 9.2.6.1. Company overview
      • 9.2.6.2. Financial performance
      • 9.2.6.3. Product benchmarking
      • 9.2.6.4. Strategic initiatives
    • 9.2.7. F. Hoffmann-La Roche Ltd.
      • 9.2.7.1. Company overview
      • 9.2.7.2. Financial performance
      • 9.2.7.3. Product benchmarking
      • 9.2.7.4. Strategic initiatives
    • 9.2.8. Camurus
      • 9.2.8.1. Company overview
      • 9.2.8.2. Financial performance
      • 9.2.8.3. Product benchmarking
      • 9.2.8.4. Strategic initiatives
    • 9.2.9. Sun Pharmaceutical Industries Ltd
      • 9.2.9.1. Company overview
      • 9.2.9.2. Financial performance
      • 9.2.9.3. Product benchmarking
      • 9.2.9.4. Strategic initiatives
    • 9.2.10. Braeburn, Inc.
      • 9.2.10.1. Company overview
      • 9.2.10.2. Financial performance
      • 9.2.10.3. Product benchmarking
      • 9.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 4 Global naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 Global naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 6 Global naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 North America naltrexone and buprenorphine market, by region, 2018 - 2030 (USD Million)
  • Table 8 North America naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 9 North America naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 North America naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 11 North America naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 U.S. naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 13 U.S. naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 U.S. naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 15 U.S. naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Canada naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 17 Canada naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Canada naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 19 Canada naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Mexico naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 21 Mexico naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22 Mexico naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 23 Mexico naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Europe naltrexone and buprenorphine market, by country, 2018 - 2030 (USD Million)
  • Table 25 Europe naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 26 Europe naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 Europe naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 28 Europe naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29 UK naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 30 UK naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 31 UK naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 32 UK naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 Germany naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 34 Germany naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 Germany naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 36 Germany naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 France naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 38 France naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 France naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 40 France naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Italy naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 42 Italy naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Italy naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 44 Italy naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Spain naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 46 Spain naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Spain naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 48 Spain naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Norway naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 50 Norway naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 51 Norway naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 52 Norway naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 Sweden naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 54 Sweden naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 55 Sweden naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 56 Sweden naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 Denmark naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 58 Denmark naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 59 Denmark naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 60 Denmark naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific naltrexone and buprenorphine market, by country, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66 Japan naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 67 Japan naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 68 Japan naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 69 Japan naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 China naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 71 China naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 72 China naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 73 China naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 India naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 75 India naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 India naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 77 India naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78 Australia naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 79 Australia naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 Australia naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 81 Australia naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 South Korea naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 83 South Korea naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 84 South Korea naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 85 South Korea naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86 Thailand naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 87 Thailand naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 88 Thailand naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 89 Thailand naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 Latin America naltrexone and buprenorphine market, by country, 2018 - 2030 (USD Million)
  • Table 91 Latin America naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 92 Latin America naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 93 Latin America naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 94 Latin America naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 95 Brazil naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 96 Brazil naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 97 Brazil naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 98 Brazil naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 99 Argentina naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 100 Argentina naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 101 Argentina naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 102 Argentina naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa naltrexone and buprenorphine market, by country, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 108 South Africa naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 109 South Africa naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 110 South Africa naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 111 South Africa naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 116 UAE naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 117 UAE naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 118 UAE naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 119 UAE naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 120 Kuwait naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 121 Kuwait naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 122 Kuwait naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 123 Kuwait naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)

List of Fig.ures

Fig. 1 Naltrexone and buprenorphine market segmentation

Fig. 2 Market research process

Fig. 3 Data triangulation techniques

Fig. 4 Primary research pattern

Fig. 5 Market research approaches

Fig. 6 Value chain-based sizing & forecasting

Fig. 7 QFD modelling for market share assessment

Fig. 8 Market formulation & validation

Fig. 9 Market snapshot

Fig. 10 Molecule and sales channel segment snapshot

Fig. 11 Competitive landscape snapshot

Fig. 12 Global Pharmaceutical Market, (USD billion)

Fig. 13 Market dynamics

Fig. 14 Porter's five forces analysis

Fig. 15 PESTLE analysis

Fig. 16 Naltrexone and buprenorphine: Product outlook and key takeaways

Fig. 17 Naltrexone and buprenorphine market: Product market movement analysis

Fig. 18 Naltrexone market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 19 Buprenorphine market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 20 BELBUCA market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 21 Sublocade market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 22 Suboxone market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 23 Zubsolv market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 24 Others market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 25 Naltrexone and buprenorphine: Route of administration outlook and key takeaways

Fig. 26 Naltrexone and buprenorphine market: Route of administration market movement analysis

Fig. 27 Naltrexone market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 28 Oral administration market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 29 Injectable administration market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 30 Implantable administration market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 31 Buprenorphine market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 32 Oral administration market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 33 Injectable administration market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 34 Implantable administration market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 35 Naltrexone and buprenorphine: Application outlook and key takeaways

Fig. 36 Naltrexone and buprenorphine market: Application market movement analysis

Fig. 37 Naltrexone market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 38 Opioid Use Disorder (OUD) market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 39 Alcohol use disorder (AUD) market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 40 Buprenorphine market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 41 Opioid Use Disorder (OUD) market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 42 Naltrexone and buprenorphine: Distribution channel outlook and key takeaways

Fig. 43 Naltrexone and buprenorphine market: Distribution channel market movement analysis

Fig. 44 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 45 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 46 Other market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 47 Naltrexone and buprenorphine market revenue, by region, 2023 & 2030, USD Million

Fig. 48 Regional marketplace: Key takeaways

Fig. 49 Regional marketplace: Key takeaways

Fig. 50 North America naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 51 Key country dynamics

Fig. 52 U.S. naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 53 Key country dynamics

Fig. 54 Canada naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 55 Key country dynamics

Fig. 56 Mexico naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 57 Regulatory framework

Fig. 58 Europe naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 59 Key country dynamics

Fig. 60 UK naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 61 Key country dynamics

Fig. 62 Germany naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 63 Key country dynamics

Fig. 64 France naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 65 Key country dynamics

Fig. 66 Spain naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 67 Key country dynamics

Fig. 68 Italy naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 69 Key country dynamics

Fig. 70 Denmark naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 71 Key country dynamics

Fig. 72 Sweden naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 73 Key country dynamics

Fig. 74 Norway naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 75 Rest of Europe naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 76 Asia Pacific naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 77 Key country dynamics

Fig. 78 Japan naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 79 Key country dynamics

Fig. 80 China naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 81 China regulatory details

Fig. 82 India naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 83 Key country dynamics

Fig. 84 Australia naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 85 Key country dynamics

Fig. 86 Thailand naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 87 Key country dynamics

Fig. 88 South Korea naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 89 Rest of Asia Pacific naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 90 Latin America naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 91 Key country dynamics

Fig. 92 Brazil naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 93 Brazil regulation details

Fig. 94 Key country dynamics

Fig. 95 Argentina naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 96 Argentina regulatory framework

Fig. 97 Rest of Latin America naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 98 Key country dynamics

Fig. 99 South Africa naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 100 Key country dynamics

Fig. 101 Saudi Arabia naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 102 Key country dynamics

Fig. 103 UAE naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 104 Key country dynamics

Fig. 105 Kuwait naltrexone and buprenorphine market estimates and forecasts, 2018

Fig. 106 Rest of MEA naltrexone and buprenorphine market estimates and forecasts,

Fig. 107 Company/competition categorization

Fig. 108 Company market share analysis, 2023

Fig. 109 Strategy mapping